Coloplast announced good Q1 20 numbers – trumping estimates on both the topline and bottomline. Sales were up 8% on an organic basis – driven by wound and skin care (+10%), ostomy (+9%), urology (+9%) – and the EBIT margin came in at 31%. Management re-iterated its FY 2020 guidance: topline growth of 7-8%, EBIT margin at ~31%, capex around DKK850m and an effective tax rate of nearly 23%. Following the Q1 numbers, we will be making minor upward revisions in our estimates.
11 Feb 2020
Solid 8% growth; good start to FY 20
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Solid 8% growth; good start to FY 20
Coloplast A/S Class B (COLO:WBO) | 0 0 1.7% | Mkt Cap: 103,237m
- Published:
11 Feb 2020 -
Author:
Virendra Chauhan -
Pages:
3
Coloplast announced good Q1 20 numbers – trumping estimates on both the topline and bottomline. Sales were up 8% on an organic basis – driven by wound and skin care (+10%), ostomy (+9%), urology (+9%) – and the EBIT margin came in at 31%. Management re-iterated its FY 2020 guidance: topline growth of 7-8%, EBIT margin at ~31%, capex around DKK850m and an effective tax rate of nearly 23%. Following the Q1 numbers, we will be making minor upward revisions in our estimates.